(NASDAQ: UNCY) Unicycive Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Unicycive Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast UNCY's revenue for 2025 to be $1,507,541,652, with the lowest UNCY revenue forecast at $70,203,890, and the highest UNCY revenue forecast at $2,944,914,169. On average, 2 Wall Street analysts forecast UNCY's revenue for 2026 to be $5,141,635,593, with the lowest UNCY revenue forecast at $685,009,244, and the highest UNCY revenue forecast at $9,598,261,942.
In 2027, UNCY is forecast to generate $7,208,931,627 in revenue, with the lowest revenue forecast at $1,329,355,838 and the highest revenue forecast at $13,088,542,171.